Abstract
can be the ther-apeutic of choice for solid tumors due to shorter circulat-ing half life and a higher tumor penetration, bothcharacteristics well suited in a radio immunotherapy(RIT) approach.Ovarian cancer is the leading cause of death among gyne-cological tumors. Standard first line therapy consists ofsurgery followed by chemotherapy cycles. About 90% ofpatients relapse with a 5-year survival rate of 5–20% [1].So far, second line chemotherapy after clinical relapse hasshown limited efficacy. With the advancement of therecombinant biotechnology, a novel approach based onhuman monoclonal antibody immunotherapy has beganto be investigated. The alfa folate receptor ( αFR), which isa 38000 Dalton anchored membrane protein, is overexpressed in more than 90% of ovarian carcinoma cells,and in 60% of other gynecological carcinomas [2]. In con-trast to normal epithelial cells, ovarian carcinoma cellsexpress this receptor on their external surface making itaccessible for binding to monoclonal antibodies.The basic concept of our project is to produce a fullhuman F(ab')
Highlights
The efficacy of mAb and their fragments in cancer therapy depends on their capacity to recognize tumor associated antigens
From a clinical point of view, intact mAb are employed in the treatment of lymphoid tumors whereas antibody fragments such as Fabs or F(ab')2 can be the therapeutic of choice for solid tumors due to shorter circulating half life and a higher tumor penetration, both characteristics well suited in a radio immunotherapy (RIT) approach
With the advancement of the recombinant biotechnology, a novel approach based on human monoclonal antibody immunotherapy has began to be investigated
Summary
Address: Biotechnology Department and Biotech Pilot Plant – Dompé pha.r.ma s.p.a., Via Campo Di Pile, 67100 L'Aquila, Italy * Corresponding author from The 4th Recombinant Protein Production Meeting: a comparative view on host physiology Barcelona, Spain. Published: 10 October 2006 Microbial Cell Factories 2006, 5(Suppl 1):P29 doi:10.1186/1475-2859-5-S1-P29. The 4th Recombinant Protein Production Meeting: a comparative view on host physiology The organisers would like to thank Novozymes Delta Ltd who generously supported the meeting. Meeting abstracts – A single PDF containing all abstracts in this supplement is available here. http://www.biomedcentral.com/content/pdf/1475-2859-5-S1-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
